WINTERMUTE BIOMEDICAL RECEIVES ETHICS APPROVAL FOR PHASE IB CLINICAL TRIAL OF SOLEXAN IN SHINGLES PATIENTS

The ZosterEase clinical trial will follow a double-blind placebo-controlled format, testing the safety and proof-of-concept efficacy of topical Solexan in 30 shingles patients. The trial will commence patient recruitment in January 2024, and will be conducted in Australia. The primary objectives of the trial are to evaluate the safety and tolerability of Solexan while also gauging potential efficacy in reducing shingles pain and accelerating lesion healing. The anticipated completion time for the trial is approximately 7-12 months.

“With an increase in the aging population, the need for an effective topical treatment that reduces shingles pain is growing year over year.” Said Dr. Alyce Mayfosh, Chief Scientific Officer, “While an effective shingles vaccine exists, adoption of the vaccine has not been widespread with approximately 30% of adults over the age of 60 fully vaccinated in the United States. Furthermore, individuals under the age of 50 are not recommended to receive the vaccine, leaving a large portion of the adult population susceptible to the development of shingles. This fact, coupled with a lack of effective treatments, means many individuals will suffer from shingles pain.”

“Shingles is caused by the reactivation of the Varicella Zoster Virus (VZV) in nerves and is characterized by severe pain that can drastically reduce the quality of life for those affected.” Said Dr. Thomas Rau, Wintermute’s Chief Executive Officer. “We are very excited to expand our program into a clinical trial with shingles patients that are suffering. We’re confident that topical Solexan is both safe and effective against herpes virus infections, and this trial is critical step in demonstrating that effect.”

Leading shingles physician and Clinical Advisor to Wintermute Biomedical, Professor Myron Levin, has stated that “Shingles is a major health burden in the U.S. (1.3 million cases a year) and is equally prevalent in every region of the world. There is a great need for an effective treatment that will safely reduce the consequences of shingles.”

In response to the critical unmet need in shingles patients, Wintermute Biomedical remains committed to developing and advancing new technology and treatments that address the widespread impact of shingles by reducing pain and enhancing lesion healing.

https://www.wintermutebiomedical.com

Hot this week

Athens shines as Europe’s Youth Entrepreneurship capital at Gen-E 2025 Festival

The heart of European youth entrepreneurship beat in Athens...

Diabeloop and SOOIL launch DBLG1 with Dana-i Pump in Germany, Distributed by Mediq

Diabeloop is pleased to announce the commercial availability of...

Israel Sanctions Human Rights Lawyers as Legal Pressure Mounts Worldwide

In a dramatic escalation of its efforts to counter...

Why did Matt Cameron leave Pearl Jam ?

🎸 Matt Cameron Exits Pearl Jam After 27 Years:...

Topics

Athens shines as Europe’s Youth Entrepreneurship capital at Gen-E 2025 Festival

The heart of European youth entrepreneurship beat in Athens...

Diabeloop and SOOIL launch DBLG1 with Dana-i Pump in Germany, Distributed by Mediq

Diabeloop is pleased to announce the commercial availability of...

Israel Sanctions Human Rights Lawyers as Legal Pressure Mounts Worldwide

In a dramatic escalation of its efforts to counter...

Why did Matt Cameron leave Pearl Jam ?

🎸 Matt Cameron Exits Pearl Jam After 27 Years:...

A Culture of Lies: How Israel’s Leadership Lost Gaza, Truth, and the Public

As Israeli Prime Minister Benjamin Netanyahu boarded a plane...

UK Bans Palestine Action: Journalists and Protesters Face Legal Minefield Under Terrorism Law

New anti-terror powers spark outrage over free speech, press...

Related Articles

Popular Categories

spot_imgspot_img